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suggesting that they reflect o some extent, distinct biological pro- 
cesses. 
Aim: to investigate whether Helix-II and CTX-II reflect distinct 
degradation mechanisms, prevailing differently in distinct areas of 
cartilage, and varying differently with age and menopausal status 
in healthy subjects. 
Methods: Immunohistochemistry was performed on full depth 
knee cartilage biopsies obtained from OA patients, and the tis- 
sue distribution of Helix-II and CTX-II immunoreactivitywas deter- 
mined. Urinary Helix-II and CTX-II were measured in 105 healthy 
women (from 26 to 90 years, mean: 59 years) and 48 healthy men 
(from 26 to 79 years, mean: 48 years). 
Results: Immunoreactivity for Helix-II, but not for CTX-II, was 
associated with the matrix of fibrillated articular surfaces. Adja- 
cent non-fibrillated surfaces were negative. Immunoreactivity for 
CTX-II, but not for Helix-II, was associated with matrix close to 
bone outgrowths into cartilage, often in areas of calcified carti- 
lage. Urinary levels of Helix-II did not change significantly with 
age or menopausal status in healthy women. Urinary levels of 
CTX-II were stable in healthy premenopausal women from age 35 
to menopause, but in contrast to Helix-II, increased markedly by 
an average of 70% (p<0.0001) after the menopause and then in- 
creased slightly but not significantly with age in postmenopausal 
women. In healthy men, there was no significant change with age 
both for urinary Helix-II and CTX-II. 
Conclusion: These differences in cartilage tissue distribution 
and relative urinary levels of Helix-II and CTX-II (i) support the 
existence of distinct mechanism of type II collagen breakdown 
during cartilage degradation; (ii) show that the prevailing break- 
down mechanism varies with the region of cartilage; and (iii) show 
that these mechanisms differ in their susceptibilities to age and 
menopause. Helix-II and CTX-II may provide distinct and com- 
plementary information on cartilage turnover. 
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INHIBITION OF TYPE II COLLAGEN DEGRADATION IN 
THE OVARIECTOMIZED RAT BY ESTROGEN AND A 
SELECTIVE ESTROGEN RECEPTOR MODULATOR: 
CORRELATION BETWEEN TYPE II COLLAGEN 
BIOMARKERS 
PG Mitchel!, MG Chambers, C Lin, D Cummins, HW Cole, RL 
Cain, L Ma, MJ Berna, CA Schmalz, BL Ackermann, KL Duffin, 
JA Dodge, HU Bryant 
Musculoskeletal Division, Eli Lilly and Company, Indianapolis, IN 
Aim of Study: To determine the effect of estrogen and a 
SERM (LY505960) on the type II collagen biomarkers CTX-II and 
NET2C, in the rat ovariectomy (ovx) model and to investigate cor- 
relations between these two biomarkers. 
Methods: Forty-two 6-month-old female virgin Sprague Daw- 
ley rats underwent ovx and an additional 6 animals were sub- 
jected to sham ovx. Daily dosing began on day four post-ovx 
and consisted of the following eight groups (six animals/group): 
sham/vehicle, ovx/vehicle, ovx/17a-estradiol @ 0.01 and 0.10 
mg/kg, ovx/LY505960 @ 0.01, 0.10, 1.0 and 10.0 mg/kg. Prior 
to sacrifice (32 days post-ovx), overnight urines were collected. 
Urine samples from each animal were analyzed for type II col- 
lagen fragments containing the C-terminal telopeptide-derived 
peptide EKGPDP (CTX-II, Cartilaps: Nordic Bioscience Diagnos- 
tics A/S) by competition ELISA. The assay for a type II colla- 
gen neoepitope (NET2C) utilized online immunoaffinity capture 
with an antibody (9A4) specific for the collagenase-generated C- 
terminal neoepitope, followed by LC/MS/MS to quantify a spe- 
cific 14 mer collagen peptide (DGPSGSDGPPGPQG). CTX-II 
and NET2C concentrations in urine were normalized to creatinine 
levels. 
The data for each analyte were converted into pmoles/mole of 
creatinine and a Box-Cox transformation carried out in order to 
stabilize variances between groups to comply with standard sta- 
tistical ANOVA assumptions. A comparison of means was per- 
formed on the transformed ata using Dunnett's test for compar- 
ing each group to the non-dosed ovx group. 
Results: At 32 days post-ovx the CTX-II concentrations had in- 
creased 4.5 fold in the ovx animals while NET2C levels had in- 
creased 3.3 fold, compared with the sham-ovx animals (p<0.01). 
In comparison to the untreated ovx animals, both doses of 17a- 
estradiol and all doses of LY505960 significantly reduced both 
CTX-II levels and NET2C levels (p<0.01). A correlation coeffi- 
cient of 0.889 (regression R 2 = 0.7904) was obtained when the 
day 32 creatinine-adjusted values of CTX-II and NET2C values 
were plotted against each other. There was a small but statis- 
tically significant (p=0.0003) shift in the linear regression rela- 
tionship (CTX-II intercept at 0.69) and, a matched pairs analysis 
demonstrated that every treatment group except the sham-ovx 
group had higher CTX-II than NET2C values. 
Conclusions: We have extended previous reports relating 
to CTX-II in the ovx model, to demonstrate that NET2C, a 
collagenase-derived C-terminal type II collagen neoepitope, is el- 
evated in ovx rats and is sensitive to treatment with either estro- 
gen or the SERM, LY505960. Experimentally, a good correlation 
between CTX-II and NET2C was observed suggesting that re- 
lease of these two-type II collagen epitopes are temporally and 
mechanistically linked. The robust inhibition of type II collagen 
degradation by LY505960 in the rat ovx model suggests that this 
compound may be evaluated for treating osteoarthritis in post- 
menopausal women. 
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ADAMTS-7 DEGRADES COMP IN A Zn 2 +- AND 
pH-DEPENDENT MANNER AND IS SIGNIFICANTLY 
UPREGULATED IN THE CARTILAGE AND SYNOVlUM OF 
PATIENTS WITH RHEUMATOID ARTHRITIS 
C Liu, K Ilalov, B Sehgal, PE Di Cesare 
Orthopaedic Surgery, NYU-Hospital for Joint Diseases, New 
York, NY 
Study aims: Our genetic screen led to the discovery of ADAMTS- 
7 as an COMP-binding protein and ADAMTS-7 binds to the EGF 
domain of COMP via its C-terminal four TSP motifs. The purpose 
of this study was to characterize the mechanism underlying the 
ADAMTS-7-mediated COMP degradation and determine whether 
ADAMTS-7 expression was altered in the arthritic onditions. 
Methods: In vitro digestion assay: purified COMP (250nM) was 
incubated with recombinant ADAMTS-7 (25nM) in buffer (50mM 
Tris-HCI, 100mM NaCI, pH 7.5) supplemented with 5mM CaCI2, 
2mM ZnCL2, 2.5mM MgCI2, or various combinations at 37°C for 
12 hr. The digested proteins were visualized with Coomassie Blue 
R250. The same digestion was also performed at various pH val- 
ues. 
Subjects: Normal cartilage and synovium were obtained from 
the knees of four patients who died of diseases unrelated to 
arthritis. OA cartilage was obtained from the distal femora of 8 
patients and RA cartilage and synovium from the knees of 4 
RA patients. Expression of ADAMTS-7 in arthritic tissues: Real- 
time PCR was performed using a sequence-specific probe and 
primers for ADAMTS-7. 18s rRNA was used as internal control. 
PCR reactions were performed with 5 ng of cDNA, 100 nM probe, 
200 nM each primer, and 10.0 i~1 of TaqMan Universal 2' PCR 
Master Mix in a 20-1d reaction volume. 
Results: Zn 2+ is essential for the cleavage of COMP by 
ADAMTS-7- A degraded COMP fragment was detectable in the 
digestion buffer with Zn 2 +but was undetectable in the digestion 
buffer with Ca 2 + or Mg 2 + used alone. In the presence of Zn 2 +, 
the addition of Ca 2 +, but not Mg 2 +changed the electrophoretic 
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mobility of the COMP digested fragment. In addition, EDTA chela- 
tor totally abolished the enzymatic activity. Take together; Zinc is 
essential for the ADAMTS7-mediated COMP degradation. 
Cleavage of COMP by ADAMTS-7 is pH-dependent- ADAMTS- 
7 generated the largest amount of COMP fragments in the range 
of physiological pH (pH 7.5) up to pH 9.5, whereas the enzyme 
did not produce visible COMP fragments when pH values lower 
than 6.5 or higher than 10.5, indicating that the digestive activity 
of ADAMTS-7 is also pH-dependent. 
Increased expression of ADAMTS-7 in the cartilage and syn- 
ovium of patients with rheumatoid arthritis - To determine 
whether the expression of ADAMTS-7 in cartilage and synovium 
is altered in OA and/or RA, a real-time PCR was performed. 
ADAMTS-7 mRNA was significantly upregulated in RA cartilage, 
and only slightly upregulated in OA cartilage, compared to the 
normal control. Further analysis of synovium samples revealed 
that the level of ADAMTS-7 was also significantly upregulated in 
RA synovium compared to normal synovium. 
Conclusion: ADAMTS-7 digests COMP in a Zn 2+- and pH- 
dependent manner. ADAMTS-7 is significantly upregulated in car- 
tilage and synovium obtained from patients with RA, suggesting 
that ADAMTS-7 plays an important role in joint degenerative dis- 
ease progression. 
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THE INHIBITION OF CARTILAGE DEGRADATION 
MARKERS EXCRETION AFTER TREATMENT WITH 
RALOXIFENE IN WOMEN WITH KNEE OSTEOARTHRITIS 
S Daniluk 1 , JE Badurski 1 , A Dobrenko 1 , EZ Jeziernicka 1 , NA 
Nowak 1 , J Buslowska 2, W Holiczer 3 
1Rheum., Centre of Osteoporosis & Osteo-Articular Diseases, 
Bialystok, Poland; 2 Sniadecki Hospital, Bialystok, Poland; 
3Technical Universi~ Bialystok, Poland 
Most drugs inhibiting bone resorption used in the treatment of 
osteoporosis decrease excretion of cartilage degradation mark- 
ers and some of them stimulate chondrocytes and showed a pro- 
tective effect on experimental arthropathies in animals. Among 
them, estrogens and raloxifene (RLX), SERM group, not only in- 
hibit bone resorption but also act receptively on chondrocytes. 
Estrogens and HRT retarded progress of knee osteoarthritis but 
there is no evidence concerning a similar effect of RLX. In our par- 
allely published work, there were statistically significant improve- 
ment of mean of WOMAC index which corelated with decrease of 
CTX-II excretion. 
The aim of the study was to evaluate the effect of the 12-month- 
therapy with RLX in middle-aged women with knee osteoarthri- 
tis (OAK) and osteopenia on cartilage degeneration and bone 
turnovers markers. 
The study was conducted in 65 women, aged 52-79, mean 65.4 
years, with diagnosed OAK according to ACR criteria and rated 
on a 3-point Kellgren - Lawrence scale, with low bone mass (BMD 
of Hip neck and/or L1-L4 vertebrae T-score between -1.0 and - 
2.5), without contraindications to be treated with RLX. Patients 
were randomly assigned in the approximate ratio 1:2 to the con- 
trol (C), or to group (E) being treated for 12 mounts with 60 mg of 
RLX p.o. per day. All the participants took Calcium up to 1200 
mg/d plus 800 IU Vit. D3 and Tramadol 1-2 x 50mg/24 hours 
in the case of pain. The evaluation of RLX effect on joint car- 
tilage was based on measurements of excreted with urine the 
cartilage-specific C-terminal tetrapeptide of type II collagen CTX- 
II/Cr and cartilage oligometric matrix protein (COMP) with ELISA 
method. The bone turnover was monitored with bone-specific al- 
kaline phosphatase (b-ALP), osteoprotegerin (OP), bone-specific 
C-terminal tetrapeptide of type I collagen (CTX-I), and soluble 
NF-kappa-B receptor activator (sRANKL) with ELISA method. 
The patients and markers were monitored before and after 3, 6, 
and 12 months of treatment with RLX. 
Results: Regressive analysis of time changes showed statisti- 
cally significant decrease in OP, CTX-II, CTX-II/Cr in the group 
treated with RLX and lack of any marker changes in the con- 
trol group. The drop of excreted CTX-II and CTX-II/Cr after 12 
months in group E was 30% and 40%, respectively with regard to 
the values before the treatment. There were neither differences 
in time and between the groups E and C as for markers of bone 
metabolism nor their correlation with markers of cartilage degen- 
eration nor COMP changes. 
Conclusion: We observed a statistically significant decrease 
in CTX-II and CTX-II/Cr excretion (with simultaneous ignificant 
lowering of WOAC index) in patients treated with RLX as com- 
pared to lack of such changes in the control group. It seems that 
RLX has a curative effect on cartilage degradation with improve- 
ment of clinical outcomes. There was no evidence on interaction 
between cartilage and bone metabolismexcept of decrease of OP. 
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FRAGMENTS OF THE C-TELOPEPTIDE OF TYPE II 
COLLAGEN CAN BE DETECTED IN CIRCULATION 
CONCOMITANTLY WITH CLINICAL EVIDENCE OF JOINT 
DISEASE IN THE COLLAGEN INDUCED ARTHRITIS (CIA) 
MODEL OF RA IN THE RAT 
S Oestergaard 1, LB Tanko 2, L Chouinard 3, N Doyle 3, SY 
Smith 3, P Qvist 1 
1R&D, Nordic Bioscience, Herlev, Denmark; 2CCBR, Ballerup, 
Denmark; 3 preclinical Services, Charles River Laboratories, 
CTBR, Montreal, Canada 
Background: Collagen induced arthritis in the rat has been ex- 
tensively studied as a model of rheumatoid arthritis (RA). Dis- 
ease activity and structural joint damage can be quantitatively as- 
sessed, and in addition biochemical markers have been adopted 
in the monitoring of disease progression in the CIA model. Helical 
fragments of type II collagen (C2C), which are generated by the 
action of aggrecanase, are slightly increased in the CIA model 
(Mayer et al, JBMR 2004;19:SA030). However, other proteases 
participating in the degradation of articular cartilage give rise to 
other collagen fragments, and therefore the present study was 
undertaken to investigate if fragments of C-telopeptide of type II 
collagen (CTX II) in circulation could reflect disease activity in this 
animal model of RA. 
Objective: To investigate the time-course of collagen type II 
degradation in circulation in the CIA model of rheumatoid arthrti- 
tis. 
Methods: Twenty, 6-week old female Lewis (LEW/SsN/CrCrlBR) 
rats were randomized into 2 groups: (I) CIA group (15 animals) 
and (11) negative control (5 animals). The immunization was 
performed once at Day 1 with porcine type II collagen. Blood 
samples were collected at day 1 (prior to immunization), 8, 15, 
18 and 23, and in addition, lavage synoviocentesis was per- 
formed at study termination. Cartilage degradation was evalu- 
ated using serum CTX-II (Nordic Bioscience, Denmark) and C2C 
(Ibex, Canada) assays. Bone resorption was estimated by CTX-I 
(Nordic Bioscience, Denmark). Paw inflammation was assessed 
semi-quantitatively using scores from 0 to 5. 
Results: CIA group developed arthritis at Day 15 after immuniza- 
tion. The cumulative macroscopic scores from tarsal and carpal 
joints (left and right) were 0.0 and 9.1 4- 1.6 (p = 0.0012) in neg- 
ative and CIA groups, respectively. Serum CTX II levels were in- 
creased 295% compared to controls at Day 15 (p = 0.0012). C2C 
was increased 12% in the CIA group, which, however, did not 
reach statistical significance. The cumulative macroscopic scores 
